Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prunella oral liquid is an herbal preparation derived from the plant Prunella vulgaris, also known as self-heal or Xiakucao in Chinese. It is used in traditional Chinese medicine and is being studied for its therapeutic effects on thyroid conditions. A clinical trial (NCT06423235) is currently evaluating its efficacy and safety for treating benign thyroid nodules. This is a post-marketing study, suggesting the product is already available in China, where it is used to treat conditions like goiter, thyroid nodules, and hyperthyroidism. The proposed mechanisms of action for Prunella vulgaris involve anti-inflammatory and immunomodulatory effects, potentially through the suppression of pathways like NF-κB and the regulation of apoptosis and oxidative stress. The plant contains numerous bioactive compounds, including triterpenoids, flavonoids (such as luteolin, quercetin, kaempferol), and phenolic acids (like rosmarinic acid), which are thought to contribute to its medicinal properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prunella oral liquid.